Literature DB >> 807632

Generation of cytotoxic T lymphocytes in vitro. V. Response of normal and immune spleen cells to subcellular alloantigens.

H D Engers, K Thomas, J C Cerottini, K T Brunner.   

Abstract

Subcellular particulate membrane fragments prepared from murine lymphoid or tumor cells were used as a cell-free antigen source in order to stimulate the generation of cytolytic thymus-derived effector cells (CTL) in vitro. When cultivated with normal spleen cells as a source of responding lymphocytes, particulate antigen preparations induced only low CTL activities; in contrast, virtually normal responses were observed when immune spleens were used as a source of responding cells. In both cases, results were compared to those responses obtained with intact irradiated (1000 rads) normal spleen cells as stimulating antigen. The effector cells generated with particulate antigen preparations (obtained either by hypotonic shock or by sonication) were shown to be T cells and were characterized with regard to the kinetics of their response and their dose-activity relationship. It was also shown that the responses observed were specific, both at the level of initiation and at the effector level. The results obtained suggest that there exists a fundamental difference between normal and alloimmune spleen cells in their ability to respond in vitro to stimulation by subcellular antigen preparations.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 807632

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Analyzing cellular immunity to AAV in a canine model using ELISPOT assay.

Authors:  Zejing Wang; Rainer Storb; Stephen J Tapscott; Stanley Riddell
Journal:  Methods Mol Biol       Date:  2012

2.  HLA-restricted epitope identification and detection of functional T cell responses by using MHC-peptide and costimulatory microarrays.

Authors:  Jennifer D Stone; Walter E Demkowicz; Lawrence J Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-23       Impact factor: 11.205

3.  Spontaneous renal allograft acceptance associated with "regulatory" dendritic cells and IDO.

Authors:  Charles H Cook; Alice A Bickerstaff; Jiao-Jing Wang; Tibor Nadasdy; Patricia Della Pelle; Robert B Colvin; Charles G Orosz
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

4.  Enhancement of the primary cytotoxic response to membrane by a lymphokine costimulator.

Authors:  K Rulon; D W Talmage
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

5.  Resistance to metabolic inactivation is a functional phenotype of radioresistant stimulating spleen cells (RSCs) in allo-CTL generation.

Authors:  T Reme; C Cognot; A Dupuy d'Angeac
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

6.  Induction of cell-mediated cytotoxicity by lipoprotein containing histocompatibility antigens.

Authors:  G Dennert
Journal:  Immunology       Date:  1979-12       Impact factor: 7.397

7.  Genetic and stimulator cell requirements for generation and activation of minor histocompatibility antigen-specific memory cytotoxic T-lymphocyte precursors.

Authors:  K I Ando; K I Isobe; T Hasegawa; T Iwamoto; R N Ding; J Rahman; Y Muro; T Yoshida; F Nagase; K Kawashima
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

8.  Activation of natural killer (NK) cells in vivo with H-2 and non-H-2 alloantigens.

Authors:  E A Clark; R D Holly
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

9.  Insertion of Ia and H-2 alloantigens into model membranes.

Authors:  D R Littman; S E Cullen; B D Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

10.  Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract.

Authors:  N Kan; K Ohgaki; T Inamoto; H Kodama
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.